|Day's range||38.30 - 38.30|
Novo Nordisk (NVO) gets CHMP recommendation approval for Sogroya for expanded use in children and adolescents with growth hormone deficiency.
Yahoo Finance Live health care reporter Anjalee Khemlani details the clinical trial results of Pfizer's weight loss drug Danuglipron, how it compares to Novo Nordisk's Ozempic, and examines the adoption of weight loss drugs in the health and wellness space.
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Bagsværd, Denmark, 26 May 2023 – Novo Nordisk today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion, recommending once-weekly Sogroya® (somapacitan) for replacement of endogenous growth hormone (GH) in children aged three years and above, and adolescents with growth failure due to growth hormone deficiency. Symptoms of growth hormone deficiency in children often start early in life, leading to short stature
The rising earnings estimate revisions are a strong sign that there could be more upside for Novartis and Novo Nordisk stock this year. Furthermore, both companies are leaders in critical areas of healthcare and remain sound long-term investments for 2023 and beyond.
Novo Nordisk (NVO) partners with Life Edit Therapeutics to discover and develop gene-editing therapies for rare and cardiometabolic diseases.
Novo Nordisk (NVO) possesses solid growth attributes, which could help it handily outperform the market.
Life Edit will receive an upfront cash payment and is eligible to receive milestone payments of 250-335 million US dollars for each of seven development programmes, as well as tiered royalties on global net sales. Life Edit has the option to a global profit share on one programme. Novo Nordisk will make an equity investment in ElevateBio, Life Edit’s parent company, as part of ElevateBio’s 401 million US dollars Series D financing. Bagsværd, Denmark and Durham, NC, US, 24 May 2023 – Novo Nordisk
Shares of the Danish pharma giant Novo Nordisk (NYSE: NVO) were down by 3.4% on elevated volume as of 1:14 p.m. ET Tuesday afternoon. The drugmaker's shares are falling in response to the strong mid-stage data for Pfizer's orally administered diabetes and weight loss drug, danuglipron, which were published yesterday in JAMA Network medical journal. Novo's shares have more than doubled in value over the prior two years, thanks to the breakout success of its type 2 diabetes and weight loss drug semaglutide.
Novo Nordisk's (NVO) late-stage study of once-daily oral semaglutide 25 mg and 50 mg in obesity shows superior weight loss at week 68 compared with placebo.
Bristol Myers' (BMY) idiopathic pulmonary fibrosis drug reduces the rate of lung function decline in a phase II study.
Data from a phase II study published in JAMA showed that Pfizer's (PFE) danuglipron reduces glycated hemoglobin and fasting plasma glucose (at all doses) and body weight (at the highest doses) at week 16.
Yahoo Finance's Rachelle Akuffo details a rise in Pfizer stock after the company announced positive results from the study of a new weight loss drug.
The FDA approves AbbVie's (ABBV) epcoritamab, to be marketed as Epkinly, for relapsed/refractory large B-cell lymphoma, a form of NHL. Epkinly is AbbVie's third blood cancer drug.
Bagsværd, Denmark, 22 May 2023 – Novo Nordisk today announced headline results from OASIS 1, a phase 3a trial in the global OASIS programme. OASIS 1 is a 68-week, efficacy and safety trial comparing once-daily oral semaglutide 50 mg for weight management to placebo in 667 adults with obesity or overweight with one or more comorbidities. Both treatment arms were in conjunction with lifestyle intervention. The trial achieved its primary endpoint by demonstrating a statistically significant and sup
Bagsværd, Denmark, 22 May 2023 – On 9 May 2023, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No 596/2014 of the European Parliament and Council of 16 April 2014 (MAR) and the Commission Delegated Regulation (EU) 2016/1052 of 8 March 2016 (the "Safe Harbour Rules"). This programme is part of the overall share repurchase programme of up to DKK 30 billion to be executed during a 12-month period beginning 1 February 2023. Under the programme-initiate
Our time-tested methodologies were at work to help investors navigate the market well last week. Here are some of our key performance data from the past three months.
Novartis (NVS) gains 10.6% year to date on strong first-quarter results and encouraging data on Kisqali from the NATALEE study.
AbbVie (ABBV) announces the seventh FDA approval of its JAK inhibitor, Rinvoq, for the treatment of adults with moderately to severely active Crohn's disease.
Novo Nordisk (NYSE: NVO) is the company behind diabetes and weight-loss treatments Ozempic and Wegovy. Business has been booming as demand for those drugs has left the company in a rush to add capacity so that it can fill orders. On Jan. 2, 2020, shares of Novo Nordisk opened at a price of $58.31.
Strong sales of key products like Keytruda and Gardasil and positive pipeline/regulatory developments should keep Merck's (MRK) stock afloat in 2023.
Bayer's (BAYRY) oral FXIa inhibitor, asundexian, gets the FDA's Fast Track Designation, as a preventive treatment for stroke and systemic embolism in people with atrial fibrillation.
The drugmaker's shares have crushed the broader markets over the past two years. Can it keep up this blistering momentum?
Momentum investing is centered around targeting stocks displaying outperformance. And when you add in the Zacks Rank, the strategy can become even more potent.